Scarica l'app Stockscreener
29.93
0.69%
0.205
Dopo l'orario di chiusura:
30.07
0.135
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$29.73
Aprire:
$30.03
Volume 24 ore:
1.51M
Relative Volume:
0.53
Capitalizzazione di mercato:
$3.72B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-14.75
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+9.09%
1M Prestazione:
-13.31%
6M Prestazione:
-24.20%
1 anno Prestazione:
-54.59%
Intervallo 1D:
$29.61
$30.35
Intervallo di 1 settimana:
$27.61
$30.35
Portata 52W:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
29.93 | 3.72B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Up 7.3% in December - MarketBeat
Hennion & Walsh Asset Management Inc. Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
IC-MPGN Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Novartis, Apellis Pharmaceuticals - The Globe and Mail
IC-MPGN Market Revenue to Expand Significantly by 2034, States - openPR
HC Wainwright Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect - AccessWire
Apellis Pharmaceuticals, Inc. Reports Financial Results and Board ChangesWALTHAM, MA–(GLOBE NEWSWIRE)–Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) recently disclosed preliminary unaudited total U.S. net product revenues for the fourth quarter a - Defense World
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals chief people officer sells $45,894 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals VP sells shares worth $22,473 By Investing.com - Investing.com Canada
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock - Investing.com India
Apellis Pharmaceuticals CFO sells shares worth $62,283 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals chief development officer sells shares worth $7,577 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $62,279.00 in Stock - MarketBeat
David O. Watson Sells 4,965 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals officer sells shares worth $77,065 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 - Investing.com India
Apellis Pharmaceuticals officer sells shares worth $77,065 - Investing.com India
Apellis Pharmaceuticals CFO sells shares worth $62,283 - Investing.com
Apellis Pharmaceuticals chief people officer sells $45,894 in stock - Investing.com India
James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $179,288.90 in Stock - MarketBeat
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 - Investing.com
Apellis Pharmaceuticals chief business officer sells shares totaling $45,894 - Investing.com
Apellis Pharmaceuticals VP sells shares worth $22,473 - Investing.com
Apellis Pharmaceuticals chief development officer sells shares worth $7,577 - Investing.com India
Apellis Pharmaceuticals' (APLS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Apellis reports $709 million in 2024 revenue, plans for growth By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation - AccessWire
Apellis stock jumps 8% on preliminary Q4 results, updates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpHere's What Happened - MarketBeat
Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes - TipRanks
Apellis reports $709 million in 2024 revenue, plans for growth - Investing.com
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Apellis Reports Strong $709M Revenue as SYFOVRE Sales Surge 120%, Announces Leadership Changes - StockTitan
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm - AccessWire
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's Why - MarketBeat
Apellis Announces Keli Walbert to Join the Board of Directors - The Manila Times
What’s Driving Apellis Pharmaceuticals Stock Down? - TipRanks
Apellis Pharmaceuticals Strengthens Board with TEPEZZA Launch Veteran Keli Walbert - StockTitan
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):